BioRunUp.com | Investing in Bio Pharmaceutical Stocks

Valuation Report on PLX Released

2010-12-28T06:30:00-00:00

We are pleased to release our valuation report on PLX.

Video Lesson - The Backbone of BioRunUp.com

2010-12-27T08:15:00-00:00

The most powerful feature of BioRunUp.com is also the least used. Watch the video below to learn how to get the most out of our "Clinical and Regulatory Bio-Catalyst Spreadsheet".

Join BioRunUp this Week and Save 40%

2010-12-26T09:24:00-00:00

We are extremely proud of the BioRunUp community. In the course of just a few months we have grown to a community of nearly 1000 members, of which 97% are actively participating.

This Week's Watchlist 12/27/10

2010-12-26T08:52:00-00:00

Back to business! We have a jam packed week coming up, so lets take a look:

Video Lesson - Options Basics

2010-12-23T09:21:00-00:00

One of the most requested video lessons has been about the basics of options trading. Take a look at the video below:

Mid-Week Update

2010-12-22T10:49:00-00:00

Although this is a holiday shortened week, it has been packed with exciting biotech action. Take a look below for a summary of this week's activity:

ACUR Submits an NDA for ACUROX Tablets

2010-12-21T08:23:00-00:00

On Monday Acura Pharmaceuticals (ACUR) quietly announced the submission of a New Drug Application for its ACUROX (oxycodone) tablets. Within this request they filed for priority review classification. Lets take a look at what this means for ACUR and its share price.

This Week's Watchlist 12/20/10

2010-12-19T20:30:00-00:00

We have a holiday shortened trading week on ahead of us, as the markets are closed on Friday for the observance of Christmas Day. Trading volume may also be lighter as many investors and traders are on vacation. However, there are still plenty of stocks to watch this week.

Twitter Trade Alerts Now Available for BioRunUp Mobile App

2010-12-17T09:09:00-00:00

The BioRunUp application is the mobile companion to BioRunUp.com, which is the best resource on the Internet for making consistent, risk-mitigated gains trading bio-pharmaceutical stocks ahead of regulatory and clinical catalyst events.

$LCI $AMRN $PSDV $EXAS $ANX BioRunUp Weekly Recap & Year-End Outlook Video

2010-12-17T08:57:00-00:00

$LCI $AMRN $PSDV $EXAS $ANX BioRunUp Weekly Recap & Year-End Outlook Video

$EXAS EXACT Sciences -- Nov. 2010 Corporate Presentation Video

2010-12-16T09:36:00-00:00

$EXAS EXACT Sciences -- Nov. 2010 Corporate Presentation w/ upcoming milestones and updated financials

DEPO Valuation Report Released

2010-12-16T06:30:00-00:00

If there ever was a 'poster child' for the Run-Up Method, it would be DEPO.

Video Lesson #2 $LCI Video Trade, Rotating Bio-Catalyst Trading Strategy

2010-12-15T09:18:00-00:00

$LCI Lannett Video Trade and the Rotating Bio-Catalyst Trading Strategy

$ANX Requests a Meeting with the FDA for a New Product- ANX-514

2010-12-15T06:37:00-00:00

As we previously discussed, ANX is awaiting a reply from the FDA on NDA acceptance of ANX-530, which should be within a month. Today ANX announced that they have just requested a meeting with the FDA to discuss..

Five Tips for Better BioTech Trading

2010-12-14T13:34:00-00:00

Click the link below to download the exclusive BioRunUp.com eBook "Five Tips for Better BioTech Trading & Understanding the BioCatalyst Process".

$LCI Lannett Prices Stock Offering Ahead of Expected FDA Decision

2010-12-14T07:47:00-00:00

Lannett (AMEX:LCI) announced details on the public offering of its common stock this morning, which was priced at $5 per share and included 2.5 million (M) shares sold by the Company (approx. 10% dilution to 25.3M shares outstanding) and 2.5M shares sold by an existing shareholder.

$LCI Lannett Spooks Investors with Plans for Public Stock Offering

2010-12-13T18:03:00-00:00

Shortly after publishing my article on Lannett Company (AMEX:LCI) earlier this afternoon, the company issued a press release after the market close indicating that it intends to sell stock to the public in order to raise money under an existing shelf registration statement with the SEC.

Video Lesson #1 - OREX Video Trade Review

2010-12-13T17:49:00-00:00

This is a test

$LCI Lannett Profit Taking Represents Buying Opportunity

2010-12-13T12:41:00-00:00

Below is an update on the current status, valuation comparisons, and my outlook for Lannett Company (AMEX:LCI) on what appears to be a profit taking sell-off today with shares trading back to around the levels that it started the month.

This Week's Watchlist 12/13/10

2010-12-11T09:54:00-00:00

Utilize the Private Twitter Feed @BioRunUpTrades

2010-12-09T07:34:00-00:00

By no means are we experts on Twitter use, but we wanted to share some information on how members can utilize our private twitter feed @BioRunUpTrades

$ENDP Endo Pharma Showing Signs of Weakness

2010-12-08T05:55:00-00:00

Written by Bill Rusnak. Endo Pharma (NASDAQ:ENDP) quietly closed 0.11 points lower today at 35.97. The company's drug Fortesta, a testosterone replacement for men, has its PDUFA action goal date coming up on 12/30/10.

Private Twitter Account Created ONLY for BioRunUp Paid Subscribers

2010-12-06T15:07:00-00:00

We have just released a private, members only, twitter feed. We have created this feed strictly to post our trades. Please read the instructions below CAREFULLY and follow them step by step...

$30M Cap Company with Cancer Drugs Awaits its NDA from the FDA

2010-12-06T07:01:00-00:00

It is not often that we get the chance to play a run-up on such a low cap biotech with a pending NDA for a cancer drug. Obviously the potential for a run-up is high. This is exactly what we have with...

Quick Reminder- OREX FDA Advisory Panel is next week

2010-12-02T09:51:00-00:00